Formulary
Lecanemab: Indications, Dosing, Side Effects and Interactions
Lecanemab is a humanised monoclonal antibody which binds to amyloid beta (A) aggregates, thereby reducing amyloid plaques in the brain.
MedNext Academy | 3 min read
Lecanemab: Indications, Dosing, Side Effects and Interactions
Lecanemab is a humanised monoclonal antibody which binds to amyloid beta (A) aggregates, thereby reducing amyloid plaques in the brain.
Drug action
Lecanemab is a humanised monoclonal antibody which binds to amyloid beta (A) aggregates, thereby reducing amyloid plaques in the brain.
Indications and dose
**Mild cognitive impairment or mild dementia in Alzheimer's disease [in apolipoprotein E 4 (ApoE4) heterozygotes or non-carriers] (under expert supervision)**
- **Adult** (By Intravenous Infusion): 10 mg/kg every 2 weeks, for dose interruption or treatment discontinuation due to side-effects-consult product literature.
Cautions
Infusion-related reactions; risk factors for intracerebral haemorrhage Cautions, further information Infusion-related reactions Infusion-related reactions can occur during or within 2.5 hours after completion of the infusion; these reactions can be managed by reducing the rate or stopping the infusion and appropriate management initiated. Pre-medication with antihistamines, paracetamol, NSAIDs, or corticosteroids may be considered for subsequent infusions. M
Contraindications
MRI findings suggestive of cerebral amyloid angiopathy-consult product literature
Side effects
Common or very common Amyloid related imaging abnormalities; atrial fibrillation; CNS haemorrhage; headache; hypersensitivity; infusion related reaction; skin reactions; superficial siderosis of central nervous system Frequency not known Fall
Interactions
**Other interactions (2):**
- No pharmacokinetic (PK) drug interactions are expected with lecanemab.
- The risk of intracerebral haemorrhage with lecanemab treatment may be increased in patients receiving anticoagulant therapy or thrombolytic agents (see sections 4.3 and 4.4).
Pregnancy
Avoid unless potential benefit outweighs risk (no information available). M
Breast feeding
Avoid (no information available). M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Lecanemab in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

